GRAIL: The FDA Advisory Committee Is Progress, But Don't Confuse It With Approval

What more does the market need to see from GRAIL before it stops punishing the stock for a trial result that didn't actually invalidate the product?

GRAIL announced Tuesday that the FDA will hold an advisory committee meeting this fall to review the Premarket Approval (PMA) application for its Galleri multi-cancer early detection test. The news arrived alongside second-quarter earnings that showed Galleri test volumes climbing 35% year-over-year to more than 61,000, and revenue growing 26% to $44.7 million. On its face, that's the profile of a company executing on a secular opportunity. And yet GRAL sits around $70, roughly 40% below its 52-week high of $118.84, after a brutal ride that once saw it touch $29.95.

The selloff has a name: the NHS-Galleri trial.

The Trial That Wasn't a Failure, Just Misread

Last spring, GRAIL's landmark randomized controlled trial in the U.K. National Health Service — the first of its kind for any multi-cancer early detection test — failed to meet its primary endpoint. The endpoint was a composite reduction in Stage III and Stage IV cancers. The result? No statistically significant difference between the screening arm and usual care.

Headlines called it negative. The stock sold off. But here's what the primary endpoint hid: Galleri reduced Stage IV diagnoses of 12 prespecified aggressive cancers by 22% in the second screening round and 26% in the third. At the same time, it detected four times as many cancers as standard screening alone, with a 128% increase in Stage I and II detections. The reason the composite endpoint didn't move is mechanical — the test shifted cancers from Stage IV to Stage III, which canceled out in the aggregate math. That's not a product failure. That's an endpoint design problem.

As one expert put it, the primary endpoint was "very hairy." A reduction in Stage IV doesn't uniformly mean cure for liver, bile duct, or pancreatic cancers, and combining Stage III and IV in one bucket obscured the actual benefit profile. The trial also ran only three years — historical screening trials that showed mortality benefit typically required 6.5 years or more of follow-up.

The bigger story from the data is what the screening arm revealed about the current system: a massive reservoir of undiagnosed cancers in the population that existing screening programs miss. Galleri found them. That's the signal investors should be tracking, not the composite endpoint that was arguably never going to move in three years.

PATHFINDER 2 Is the Stronger Dataset

If NHS-Galleri was the proof-of-concept, PATHFINDER 2 is the closer look. The prospective U.S. study of 35,878 participants showed that adding Galleri to recommended screenings increased cancer detection 6.5-fold. The positive predictive value — the chance that a positive test actually finds cancer — was 60.3%. For comparison, low-dose chest CT for lung cancer and mammography both run in the single digits. Specificity held at 99.6%, meaning false positives are rare. Cancer Signal Origin — the test's ability to tell you where the cancer is — was correct 91.3% of the time.

This is the dataset GRAIL built its PMA submission on, along with the prevalent screening round from NHS-Galleri and a bridging analysis to the updated test version. The advisory committee meeting is the FDA's way of stress-testing that package before making a decision.

The Financials: Growing Pain, Literal Pain

The revenue trajectory is the right direction. Galleri revenue hit $42.6 million in Q2, up 24% year-over-year. Test volumes are accelerating faster than revenue, which suggests pricing pressure or mix effects but validates demand. The Samsung partnership — an $110 million equity investment for South Korea commercialization — signals a real international expansion path.

But the burn is brutal. Q2 net loss was $110.2 million, or $2.56 per share. First-half losses totaled $203.4 million. Annualized, that's roughly $400 million a year. Against a cash position of $861.6 million as of June 30, that gives GRAIL roughly two years of runway. The company has also issued substantial equity over the past two years — $1.24 billion in 2024 and $423 million in the first three quarters of 2025 — which means dilution is already baked into the per-share math.

Two years is adequate but not comfortable. It's enough to get through the advisory committee and a potential FDA decision. It's not enough to build out reimbursement infrastructure, international commercial operations, and the sales apparatus that would be needed if approval comes. That means more dilution is likely, regardless of the regulatory outcome.

The Valuation Gap

At roughly $2.94 billion market cap on $44.7 million in quarterly revenue, GRAIL trades at about 16 times forward sales. There are no earnings, so the traditional GARP framework — comparing forward P/E to growth rate — doesn't apply here. This is a binary event stock, not a growth-at-a-reasonable-price setup.

The $2.94 billion price tag means the market has already priced in a meaningful probability of FDA approval. It hasn't priced in guaranteed reimbursement, guaranteed volume at scale, or a path to profitability. The 40% drawdown from highs reflects the tension between the clinical promise and the commercial uncertainty.

The stock also faces competitive pressure. Freenome's blood-based colorectal cancer test was just included in updated American Cancer Society guidelines and is under FDA review with approval anticipated in 2026, backed by an Exact Sciences commercialization deal worth up to $885 million. That doesn't threaten Galleri's multi-cancer scope, but it normalizes the concept of blood-based screening for payers and providers — which helps GRAIL's market education even as it fragments the single-cancer blood test space.

What the Advisory Committee Actually Means

An FDA advisory committee meeting is not approval. It's a signal that the FDA has reviewed the PMA package and wants external experts to weigh in before the agency makes its call. For a Breakthrough Device like Galleri — designated back in 2018 — it's the expected next step, not a guarantee of a favorable outcome.

The advisory committee's questions will likely center on clinical utility: does earlier detection actually improve patient outcomes? GRAIL's answer right now is the Stage IV reduction, the emergency presentation decrease, and the quadrupled detection rate. But the absence of mortality data — which the trial was too short to capture — will be the bears' central argument.

The Risk/Reward Read

Here's the setup as I see it. The market has arguably baked in too much pessimism about the NHS trial after focusing on a composite endpoint that mechanically canceled out the product's strongest signal. The PATHFINDER 2 data is robust. Test volumes are accelerating. The cash runway covers the regulatory timeline. Samsung's investment validates the international thesis.

But this isn't a falling-knife contrarian buy. It's a binary event play where the stock already reflects significant approval probability. The $110 million-per-quarter burn rate means every quarter without approval or meaningful reimbursement progress is a quarter of evaporating cash and likely dilution.

The risk/reward is arguably constructive from here, but I don't think investors need to chase entry at $70. The better setup is to watch the advisory committee outcome. If the committee leans supportive and the stock pulls back on near-term uncertainty — a common pattern around these events — that's where the lower-risk entry sits. If the committee is neutral or raises material concerns, the market will likely discount approval probability, and the stock could revisit the $40-to-$50 range, where the risk/reward becomes more compelling.

For existing holders, the position is defensible. The clinical data supports the long-term thesis, and the cash runway gives the company room to navigate the regulatory process. New money is better positioned on the other side of the fall advisory committee, when the binary risk has partially resolved.

I'd reassess the bullish case if the quarterly burn rate accelerates beyond the current trajectory, if the advisory committee signals material clinical utility concerns, or if test volume growth decelerates below 20% year-over-year — the point where demand skepticism starts to outweigh the clinical narrative. Until then, GRAIL's setup is patient capital waiting for a regulatory inflection, not a stock that's been unfairly punished by noise.

Don't let the NHS headline cloud the clinical reality, but don't confuse an advisory committee meeting with a finish line either. The smart money here waits for clarity before committing the full position.